Prof Fabrice Barlesi speaks to ecancer about the ESMO 2020 virtual congress concerning sotorasib for non-small cell lung cancer (NSCLC).
The patients involved had solid tumours harbouring KRAS p.G12C mutations.
Prof Barlesi explains the adverse events, efficacy, and future prospects for the drug.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.